Results 91 to 100 of about 50,237 (216)

Mechanisms of acquired resistance to cetuximab: role of interleukin 1

, 2016
Cetuximab (CX) is a monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR), which is commonly utilized to treat patients with metastatic colorectal cancer (mCRC).
Maria Teresa Rodia, Elisabetta Caramelli, Yosef Yarden, Moshit Lindzen, Mattia Lauriola., Michela Pucci, Rossella Solmi, Massimiliano Bonafè, Valerio Gelfo   +8 more
core   +1 more source

SHP2 in Cancer: From Tumor Biology to Therapeutic Targeting

Medicinal Research Reviews, EarlyView.
ABSTRACT SHP2 is a tyrosine phosphatase that mediates intracellular signaling downstream of transmembrane receptors regulated by a pair of src homology 2 (SH2) domains. Its overexpression and mutation are pivotal in driving tumor progression by influencing various cancer's fundamental characteristics, such as metastasis, DNA repair, angiogenesis ...
Maryam Jama, Michael Overduin, Khaled H. Barakat   +2 more
wiley   +1 more source

PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models

Cells, 2018
Epidermal growth factor receptor (EGFR) is overexpressed and considered as a proper molecular target for diagnosis and targeted therapy of esophageal squamous cell carcinoma (ESCC).
Tae Sup Lee, In Ho Song, Jong Il Shin, Yong Serk Park, Jung Young Kim, Kwang Il Kim, Yong Jin Lee, Joo Hyun Kang   +7 more
doaj   +1 more source

Utility of serum anti-cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab

, 2017
International audienceAIM Cetuximab is an anti-epidermal growth factor receptor antibody used for the treatment of metastatic colorectal cancer and head and neck cancer. Hypersensitivity reactions (HSRs) are associated with cetuximab use.
Gervais, Radj, Reimund, Jean-Marie, Dupont, Benoit, Dugue, Audrey E., Chauffert, Bruno, Bouhier-Leporrier, Karine, Florescu, Carmen, Mailliez, Audrey, Dakpé, Stéphanie, Peytier, Annie, Do, Pascal, Clarisse, Benedicte, Babin, Emmanuel, Le Mauff, Brigitte, Moldovan, Cristian, Grellard, Jean-Michel, Schott, Roland, Zanetta, Sylvie, Galais, Marie-Pierre, Di Fiore, Frederic, Mariotte, Delphine   +20 more
core   +1 more source

The efficacy of concurrent chemoradiotherapy with or without nimotuzumab in high‐risk patients with locally advanced head and neck squamous cell carcinoma post‐surgery: A real‐world study

Precision Radiation Oncology, EarlyView.
Figure 1 Patient selection flowchart. CCRT, concurrent chemoradiotherapy; NCCRT, nimotuzumab and concurrent chemoradiotherapy. Abstract Purpose Patients with locally advanced head and neck squamous cell carcinoma (LA‐HNSCC) harboring high‐risk pathological features after radical surgery face high recurrence rates.
Yuejia Zhou, Linting Zhang, Wenjuan Lai, Jingyun Tan, Jing Gao, Yajie Liu, Shubin Wang, Feng Peng, Gangling Tong   +8 more
wiley   +1 more source

Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials

Gastroenterology Research and Practice, 2015
Purpose. The addition of cetuximab to radiochemotherapy (RCT) failed to improve complete response rates in locally advanced rectal cancer (LARC). We report the long-term results in patients treated within two sequential clinical trials. Methods. Patients
M. Kripp, K. Horisberger, S. Mai, P. Kienle, T. Gaiser, S. Post, F. Wenz, K. Merx, R.-D. Hofheinz   +8 more
doaj   +1 more source

Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 540-550, March 2025.
ABSTRACT We employed a mechanistic learning approach, integrating on‐treatment tumor kinetics (TK) modeling with various machine learning (ML) models to address the challenge of predicting post‐progression survival (PPS)—the duration from the time of documented disease progression to death—and overall survival (OS) in Head and Neck Squamous Cell ...
Kevin Atsou, Anne Auperin, Jôel Guigay, Sébastien Salas, Sebastien Benzekry   +4 more
wiley   +1 more source

AAVrh.10- mediated expression of cetuximab.

, 2016
A. Design of the AAVrh.10CetMap vector expressing anti-EGFR (cetuximab). The antibody cDNA construct includes the heavy chain, a furin recognition cleavage site upstream of a 2A sequence (Furin 2A) and the light chain.
Eric Aronowitz (3202374), Stephen M. Kaminsky (451257), Viviane Tabar (76491), Douglas Ballon (3202377), Kosuke Funato (3202371), David Havlicek (2285938), Ronald G. Crystal (124719), Dolan Sondhi (451254), Maria J. Chiuchiolo (102786), Martin J. Hicks (3202380), Fan Fan (341438), Jonathan P. Dyke (3202368)   +11 more
core   +1 more source

Deciphering Molecular Charge Anisotropy: The Case of Antibody Solutions

Small, EarlyView.
Molecular charge anisotropy emerges as a key determinant of antibody solution behavior. A multiscale framework combining electrostatic mapping, coarse‐grained simulations, and machine‐learning‐assisted optimization identifies charge patterns that reproduce experimental structure factors and predict collective properties across concentration, revealing ...
Fabrizio Camerin, Susana Marín‐Aguilar, Anna Stradner, Peter Schurtenberger, Emanuela Zaccarelli   +4 more
wiley   +1 more source

Mechanisms of acquired resistance to cetuximab: role of interleukin-1

, 2017
Cetuximab (CX) is a monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR), which is commonly utilized to treat patients with metastatic colorectal cancer (mCRC).
Maria Teresa Rodia, Elisabetta Caramelli, Yosef Yarden, Moshit Lindzen, Mattia Lauriola, Michela Pucci, Rossella Solmi, Massimiliano Bonafè, Valerio Gelfo   +8 more
core   +1 more source